Nang Kuang Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Nang Kuang Pharmaceutical has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 5.1% per year. Nang Kuang Pharmaceutical's return on equity is 5.2%, and it has net margins of 5.7%.
Key information
3.4%
Earnings growth rate
3.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 5.1% |
| Return on equity | 5.2% |
| Net Margin | 5.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings
Nov 19
Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings
May 22Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings
Apr 02Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet
Mar 20Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)
Mar 03Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?
Feb 13
Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years
Jan 26Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)
Jan 08Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend
Nov 29Revenue & Expenses Breakdown
How Nang Kuang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,137 | 122 | 338 | 167 |
| 30 Jun 24 | 2,094 | 111 | 331 | 169 |
| 31 Mar 24 | 2,106 | 159 | 332 | 167 |
| 31 Dec 23 | 2,150 | 198 | 332 | 164 |
| 30 Sep 23 | 2,235 | 395 | 258 | 154 |
| 30 Jun 23 | 2,189 | 423 | 254 | 149 |
| 31 Mar 23 | 2,138 | 405 | 242 | 147 |
| 31 Dec 22 | 1,940 | 352 | 229 | 144 |
| 30 Sep 22 | 1,789 | 242 | 212 | 143 |
| 30 Jun 22 | 1,763 | 213 | 204 | 140 |
| 31 Mar 22 | 1,733 | 192 | 203 | 137 |
| 31 Dec 21 | 1,780 | 196 | 206 | 134 |
| 30 Sep 21 | 1,758 | 192 | 210 | 143 |
| 30 Jun 21 | 1,718 | 176 | 209 | 146 |
| 31 Mar 21 | 1,698 | 165 | 213 | 157 |
| 31 Dec 20 | 1,755 | 183 | 212 | 160 |
| 30 Sep 20 | 1,826 | 216 | 237 | 153 |
| 30 Jun 20 | 1,871 | 247 | 245 | 147 |
| 31 Mar 20 | 1,865 | 245 | 241 | 139 |
| 31 Dec 19 | 1,762 | 217 | 240 | 131 |
| 30 Sep 19 | 1,674 | 161 | 213 | 127 |
| 30 Jun 19 | 1,563 | 110 | 206 | 136 |
| 31 Mar 19 | 1,537 | 99 | 214 | 149 |
| 31 Dec 18 | 1,539 | 101 | 217 | 155 |
| 30 Sep 18 | 1,564 | 129 | 218 | 173 |
| 30 Jun 18 | 1,575 | 153 | 229 | 161 |
| 31 Mar 18 | 1,531 | 158 | 222 | 143 |
| 31 Dec 17 | 1,504 | 186 | 219 | 136 |
| 30 Sep 17 | 1,420 | 203 | 226 | 116 |
| 30 Jun 17 | 1,434 | 211 | 222 | 119 |
| 31 Mar 17 | 1,493 | 225 | 228 | 116 |
| 31 Dec 16 | 1,550 | 225 | 230 | 116 |
| 30 Sep 16 | 1,608 | 212 | 233 | 120 |
| 30 Jun 16 | 1,601 | 233 | 234 | 113 |
| 31 Mar 16 | 1,571 | 227 | 232 | 109 |
| 31 Dec 15 | 1,520 | 199 | 232 | 106 |
| 30 Sep 15 | 1,468 | 188 | 225 | 95 |
| 30 Jun 15 | 1,451 | 153 | 220 | 96 |
| 31 Mar 15 | 1,363 | 109 | 212 | 101 |
| 31 Dec 14 | 1,277 | 67 | 203 | 114 |
| 30 Sep 14 | 1,218 | 19 | 201 | 125 |
| 30 Jun 14 | 1,106 | -7 | 195 | 118 |
| 31 Mar 14 | 1,056 | -14 | 195 | 121 |
| 31 Dec 13 | 1,013 | -8 | 193 | 104 |
Quality Earnings: 1752 has a large one-off loss of NT$63.2M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 1752's current net profit margins (5.7%) are lower than last year (17.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1752's earnings have grown by 3.4% per year over the past 5 years.
Accelerating Growth: 1752's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1752 had negative earnings growth (-69.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.9%).
Return on Equity
High ROE: 1752's Return on Equity (5.2%) is considered low.